A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

In addition to these quarterly earnings, Merck & Co., Inc. (NYSE:MRK) has shown its resilience as a dividend stock. The ...

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...

Merck's antibody-based shot met the main goal of a mid-to-late stage trial, when tested to protect infants against a disease caused by the respiratory syncytial virus (RSV), the company said on ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season. Skip to content Main Navigation ...

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.

Merck won approval from the U.S. Food and Drug Administration for a shot that protects against RSV, the most common cause of hospitalization among infants, STAT notes.